The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
40 U/µg. One unit is defined as the amount of enzyme that will transfer 1 pmol phosphate to Tyr substrate per minute at pH 7.4 and 30°C. Assay buffer: 50 mM HEPES, pH 7.4, 3 mM MgCl2, 3 mM MnCl2, 1 mM DTT, 3 µM Na-orthovanadate, 0.1 mM ATP, 30 µg/ml Poly (Glu:Tyr)4:1 substrate and 4 µg/ml recombinant c-Met.
This protein was expressed in a Baculovirus infected Sf9 cell expression system.
Concentration information loading...
Shipped on Dry Ice. Upon delivery aliquot. Store at -80°C. Avoid freeze / thaw cycle.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Hepatocyte growth factor receptor
Met proto oncogene tyrosine kinase
MET proto oncogene, receptor tyrosine kinase
Met proto-oncogene (hepatocyte growth factor receptor)
Scatter factor receptor
Tyrosine-protein kinase Met
Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
Note=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein. Note=Defects in MET may be associated with gastric cancer. Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550]. Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes. Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
Belongs to the protein kinase superfamily. Tyr protein kinase family. Contains 3 IPT/TIG domains. Contains 1 protein kinase domain. Contains 1 Sema domain.
The kinase domain is involved in SPSB1 binding.
Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
SDS-PAGE - Active human Met (c-Met) recombinant protein fragment (ab42612)
10% SDS-PAGE Gel, Stained with Coomassie Blue, 4μg of ab42612 loaded onto Gel.
Functional Studies - Active human Met (c-Met) recombinant protein fragment (ab42612)
Specific Activity: 64pmol/min/ug. cMet was incubated with 2uM substrate (Tyr2 peptide) for 1h at 30°C in a buffer containing 50mM HEPES (ph7.5), 10mM MgCl2, 1mM EDTA, 0.01% BRIJ-35 and 200uM ATP. Developer solution was added to reaction and reaction was stopped after 1h of incubation at RT.
has not yet been referenced specifically in any publications.